A report released by the American Association of Physicians and Surgeons (AAPS) has revealed that the malaria drug Hydroxylchloroquine has a 90 percent success rate in the treatment of COVID-19 patients.
In a letter to Governor Doug Ducey of Arizona, the professional association presented updated data on results from treatment of COVID-19 patients with Hydroxylchloroquine (HCQ, Plaquenil®) and Chloroquine (CQ).
According to the data presented, 2,333 patients were treated with Hydroxylchloroquine, Zinc and Azithmromycin in China, South Korea, United States, France and Algeria.
Of this number, 2,137 patients, representing 91.5% of the sample population recovered from the COVID-19. 63 of the patients died; 11 of them were severely ill before treatment was administered.
According to the professional medical association, the malaria drug has been under study since 2003 and had proven to work well when combined with Zinc.
The combination of both drugs prevent viruses from infiltrating cells, it is also able to stop replication of viruses already in the cell.
The combo is also effective in preventing overreaction of the immune system thereby preventing cytokinesis storms that induce severe COVID-19 cases. Asides from the treatment of lupus and arthritis.
The AAPS stated further that treatment of COVID-19 patients with Hydroxylchloroquine will reduce the period of infection, reduce the need for ventilators and cut recovery time significantly.
The letter also stated that peer reviewed studies have shown that usage of the drug in the early stages of the viral infection has proven to be very effective.
According to worldometers.info, deaths per million persons from COVID-19 as of Apr 27 are 167 in the U.S., 33 in Turkey, and 0.6 in India.”
Vaccines and results of randomized double-blind controlled trials of new drugs are at best months away. But patients are dying now, while affordable, long-used drugs would be available except for government restrictions,” the AAPS concluded.